Destiny Pharma plc (DEST.L)

15.75 0.00 (0.00%) At close: 04:40PM BST

Destiny Pharma plc

Sussex Innovation Centre
Unit 36 Science Park Square Falmer
Brighton BN1 9SB
United Kingdom
44 1273 704440
https://www.destinypharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 15

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Christopher John Tovey BSc	CEO & Director	123k	N/A	1965
Dr. William Guy Love	Founder, Chief Scientific Officer & Director	250k	N/A	1962
Mr. Shaun Claydon ACA	CFO, Company Secretary & Director	270k	N/A	1968
Dr. Debra Barker M.D., MSc.	Interim CMO & Senior Independent Director	213k	N/A	1962

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.

Corporate governance

Destiny Pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.